文献速递胸部肿瘤乳腺癌支持与姑息治疗

美国基于人群的癌症患者PROMIS症状与功能状态参考值估计

United States Population-Based Estimates of Patient-Reported Outcomes Measurement Information System Symptom and Functional Status Reference Values for Individuals With Cancer.
PubMed 文献 · J Clin Oncol · 2017-04-20

研究基于美国SEER项目招募2010至2012年新诊断的7类癌症患者5284例,于诊断后6至13个月邮寄问卷,按种族、年龄和分期加权生成8个PROMIS领域的参考值。癌症患者疼痛干扰、疲劳和身体功能参考值差于美国一般人群常模50分,肺癌和宫颈癌症状负担最高,晚期患者功能更差。

要点

  • 癌症患者疼痛干扰52.4、疲劳52.2、身体功能44.1,均差于一般人群常模50分。
  • 肺癌疼痛干扰55.5、疲劳57.3、抑郁51.4;宫颈癌焦虑53.2、睡眠障碍53.4。
  • 晚期患者身体功能41.1 vs 46.6、疲劳55.8 vs 50.2、疼痛干扰55.2 vs 50.9,均差于局限或无疾病证据者。

核心结论

  • 在大规模基于人群的新诊断癌症样本中,观察到症状严重程度和功能缺陷随年龄、分期和癌症类型变化,与癌症诊断和治疗的预期影响一致。
  • 这些美国癌症参考值可帮助解读研究和临床应用中PROMIS领域评分,以测量和评估患者初始治疗后的症状与功能负担。

研究设计与样本

  • 测量你的健康(MY-Health)研究通过美国国家癌症研究所SEER项目招募2010至2012年新诊断癌症患者(前列腺癌、结直肠癌、非小细胞肺癌、非霍奇金淋巴瘤、乳腺癌、子宫癌或宫颈癌),共5284例。
  • 参与者在诊断后6至13个月收到邮寄问卷。
  • 按种族/民族、年龄和分期进行耙平加权生成8个PROMIS领域的加权平均评分:疼痛干扰、疲劳、焦虑、抑郁、睡眠障碍、身体功能、参与社会角色的能力和认知功能。
  • PROMIS测量标准化为T评分 metric,50分代表美国一般人群均值。
  • 临床有意义的差异定义为评分相差3分。

主要发现

  • 癌症患者疼痛干扰参考值为52.4、疲劳为52.2、身体功能为44.1,均差于美国一般人群常模50分。
  • 肺癌患者疼痛干扰55.5、疲劳57.3、抑郁51.4;宫颈癌患者焦虑53.2、睡眠障碍53.4。
  • 65至84岁患者报告的睡眠障碍、焦虑和抑郁低于年轻患者,认知功能优于年轻患者。
  • 晚期疾病患者身体功能41.1 vs 局限或无疾病证据者46.6,疲劳55.8 vs 50.2,疼痛干扰55.2 vs 50.9。

关键数值与推荐

  • PROMIS评分50分代表美国一般人群均值,临床有意义的差异定义为评分相差3分。
  • 癌症患者参考值:疼痛干扰52.4、疲劳52.2、身体功能44.1。
  • 肺癌参考值:疼痛干扰55.5、疲劳57.3、抑郁51.4;宫颈癌参考值:焦虑53.2、睡眠障碍53.4。
  • 晚期疾病 vs 局限或无疾病证据者:身体功能41.1 vs 46.6,疲劳55.8 vs 50.2,疼痛干扰55.2 vs 50.9。

临床怎么用

  • 这些美国癌症参考值可帮助在研究或临床应用中解读PROMIS领域评分,以测量和评估患者初始治疗后的症状与功能负担。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose To estimate cancer population-based reference values in the United States for eight PROMIS (Patient-Reported Outcomes Measurement Information System) domains by age and stage of disease. Patients and Methods For the Measuring Your Health (MY-Health) study, persons newly diagnosed with cancer (prostate, colorectal, non-small-cell lung, non-Hodgkin lymphoma, breast, uterine, or cervical) from 2010 to 2012 (N = 5,284) were recruited through the National Cancer Institute's SEER Program. Participants were mailed surveys 6 to 13 months after diagnosis. Raking by race/ethnicity, age, and stage generated weighted average PROMIS scores for pain interference, fatigue, anxiety, depression, sleep disturbance, physical function, ability to participate in social roles, and cognitive function. PROMIS measures are standardized to a T-score metric, with a score of 50 representing the general US population mean. Clinically meaningful differences were defined as a 3-point difference in scores. Results Several reference values (means) for patients with cancer were worse than the general United States population norms of 50. These include pain interference (52.4), fatigue (52.2), and physical function (44.1). Reference values were highest (ie, showed greatest symptom burden) in lung cancer (pain interference, 55.5; fatigue, 57.3; depression, 51.4) and cervical cancer (anxiety, 53.2; sleep disturbance, 53.4). Reference values for patients age 65 to 84 years reported lower sleep disturbance, anxiety, and depression, and better cognitive function than younger patients. Cancer reference values were poorer among those with advanced disease compared with patients with limited or no evidence of disease, specifically physical function (41.1 v 46.6, respectively), fatigue (55.8 v 50.2, respectively), and pain interference (55.2 v 50.9, respectively). Conclusion In a large, population-based sample of patients with recently diagnosed cancer, we observed symptom severity and functional deficits by age, stage, and cancer type consistent with the expected impact of cancer diagnosis and treatment. These United States cancer reference values can help facilitate interpretation of the PROMIS domain scores in research studies or in clinical applications that measure and evaluate the symptom and functional burden patients with cancer experience after initial treatment.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Jensen RE, Potosky AL, Moinpour CM, et al. United States Population-Based Estimates of Patient-Reported Outcomes Measurement Information System Symptom and Functional Status Reference Values for Individuals With Cancer. J Clin Oncol. 2017. PMID: 28426375. doi:10.1200/JCO.2016.71.4410

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。